Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS

This study has been completed.
Information provided by:
Biogen Identifier:
First received: September 13, 2005
Last updated: September 12, 2013
Last verified: April 2011